Recurrent Melanoma Terminated Phase 2 Trials for Selumetinib (DB11689)

Also known as: Melanoma Recurrent

IndicationStatusPhase
DBCOND0028662 (Recurrent Melanoma)Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01166126Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IVTreatment
NCT01519427Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or DabrafenibTreatment